Royal Bank of Canada
CLYM

Royal Bank of Canada’s Climb Bio CLYM Stock Holding History

Royal Bank of Canada’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Sell
79
-329
-81% -$1.9K ﹤0.01% 7834
2025
Q4 		$1K Sell
408
-283
-41% -$680 ﹤0.01% 7081
2025
Q3 		$1K Sell
691
-2,161
-76% -$4.01K ﹤0.01% 7056
2025
Q2 		$4K Sell
2,852
-1,744
-38% -$2.17K ﹤0.01% 6711
2025
Q1 		$6K Sell
4,596
-96
-2% -$156 ﹤0.01% 6327
2024
Q4 		$8K Buy
4,692
+1,224
+35% +$4.43K ﹤0.01% 6426
2024
Q3 		$17K Buy
3,468
+2,782
+406% +$19.7K ﹤0.01% 6165
2024
Q2 		$5K Buy
686
+623
+989% +$4.15K ﹤0.01% 6559
2024
Q1 		$0 Buy
63
+27
+75% +$74 ﹤0.01% 7712
2023
Q4 		$0 Sell
36
-20
-36% -$52 ﹤0.01% 7680
2023
Q3 		$0 Sell
56
-69
-55% -$188 ﹤0.01% 7703
2023
Q2 		$0 Buy
+125
New +$380 ﹤0.01% 7735
2022
Q4 		– Sell
-111
Closed – – 7818
2022
Q3 		$0 Buy
111
+83
+296% +$265 ﹤0.01% 7957
2022
Q2 		$0 Sell
28
-342
-92% -$1.62K ﹤0.01% 7792
2022
Q1 		$3K Sell
370
-1,233
-77% -$11.5K ﹤0.01% 7416
2021
Q4 		$17K Buy
1,603
+823
+106% +$12.3K ﹤0.01% 6870
2021
Q3 		$14K Buy
+780
New +$16.1K ﹤0.01% 6848

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Royal Bank of Canada's CLYM Position: Q1 2026 in Review

Royal Bank of Canada reduced its Climb Bio (CLYM) stake by 81% in Q1 2026, selling an estimated $1.9K and leaving 79 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7834.

Royal Bank of Canada first reported a position in CLYM in Q3 2021 and has held it in 17 quarters since. The position peaked at $17K in Q3 2024. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

  • Royal Bank of Canada held 79 shares of Climb Bio worth $0 as of Q1 2026.
  • Royal Bank of Canada sold 329 Climb Bio shares in Q1 2026, an estimated $1.9K.
  • Climb Bio made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7834 holding.
  • Royal Bank of Canada first reported a position in Climb Bio in Q3 2021 and has held it in 17 quarters since.
  • Royal Bank of Canada's Climb Bio position peaked at $17K in Q3 2024.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.